search
Back to results

PET Study of the Nicotinic System in Epilepsy (NICOPET)

Primary Purpose

Epilepsy

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
MRI of the brain
PET scan [18F]F-A-85380
PET scan [18F]FDG
Sponsored by
Fabienne PICARD
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Epilepsy

Eligibility Criteria

18 Years - 60 Years (Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

  • males
  • 18-60 years old
  • non-smokers

Exclusion Criteria:

  • smoking during the past twelve months
  • contraindications to MRI
  • brain lesions on MRI (including hippocampal atrophy)
  • neurological disorder (other than epilepsy) or psychiatric disorder
  • neoplasia or coronary disease
  • blood test showing : creatinine clearance < 50 ml/min, or platelet < 100 G/l, or leucocytes < 3.8 G/l, or ALT or AST > 2 x upper standard, or gamma-GT > 3 x upper standard, or albumin < 35 g/l or > 48 g/l .
  • patients only : nuclear imaging during the past twelve months
  • healthy volunteers only : ionising radiation exam during the past five years

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm 4

    Arm 5

    Arm Type

    Active Comparator

    Experimental

    Experimental

    Experimental

    Experimental

    Arm Label

    Control group

    Non lesional diurnal partial epilepsy

    Idiopathic generalized epilepsy

    Nocturnal frontal lobe epilepsy

    Epileptic patients with Vagus Nerve Stimulation (VNS)

    Arm Description

    Outcomes

    Primary Outcome Measures

    Comparison of the cerebral distribution of the neuronal nicotinic acetylcholine receptors (nAChR) in the 5 groups of individuals by means of voxelwise and regional 18F-FA binding potential measurements
    Parametric 18F-FA and 18F-FDG binding potential measurements will be compared between the different groups of patients with epilepsy and the control group in order to find specific changes in the cerebral distribution of the nicotinic receptors in the different types of epilepsy, by using a voxel-wise (SPM) and a volume of interest (VOI) analysis.

    Secondary Outcome Measures

    Full Information

    First Posted
    August 24, 2017
    Last Updated
    August 30, 2017
    Sponsor
    Fabienne PICARD
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03268369
    Brief Title
    PET Study of the Nicotinic System in Epilepsy
    Acronym
    NICOPET
    Official Title
    PET Study of the Nicotinic System in Epilepsy
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    August 2017
    Overall Recruitment Status
    Completed
    Study Start Date
    February 2012 (Actual)
    Primary Completion Date
    November 2015 (Actual)
    Study Completion Date
    November 2015 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor-Investigator
    Name of the Sponsor
    Fabienne PICARD

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Mutations in neuronal nicotinic acetylcholine receptors (nAChRs) have been identified in the autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE). Despite the demonstration of a gain of function of the mutated receptors, the precise mechanisms leading to this nocturnal epilepsy are still unknown. In 2006 the investigators studied the nAChR cerebral distribution in a group of patients with ADNFLE carrying a nAChR mutation, by a PET-scan using [18F]-F-A-85380, a ligand with a high affinity and specificity for alpha4beta2 nicotinic receptors. The study showed a different pattern of brain distribution of the radiotracer in the ADNFLE patients when compared to a group of control subjects, with a significant increase of nicotinic receptor density in the patients in mesencephalon and cerebellum (Picard et al., Brain 2006). Based on the known biochemical and cellular circuits in the brainstem, these results suggest that the nAChR density increase in mesencephalon is involved in the pathophysiology of ADNFLE through the role of brainstem ascending cholinergic systems in arousal. The follow-up step consists of extending this examination to other forms of epilepsy, in order to verify the specificity of the hyperfixation pattern for ADNFLE, and search for a potential involvement of nicotinic receptors in other forms of epilepsy. The investigators aim to study 5 groups of subjects: control subjects (Group 1, 20 subjects); patients with a non lesional partial epilepsy and a predominance of diurnal seizures (Group 2, 12 subjects); patients with an idiopathic generalized epilepsy (Group 3, 12 subjects); patients with nocturnal frontal lobe epilepsy (Group 4, 3 subjects) and epileptic patients with vagal nerve stimulation (Group 5, 1 subject). For each patient, a cerebral MRI, [18F]- fluorodeoxyglucose (FDG) PET/CT and [18F]-F-A-85380 PET/CT examinations are planned. The investigators will perform data analyses on volume of distribution (Vt) parametric images which will be based on the ratio of brain tissue to unchanged F-A-85380 plasma at equilibrium. Statistical parametric mapping (SPM2) will be used to further study the parametric PET images. This study is primarily dedicated to demonstrate that the pattern of hyperfixation that was obtained in ADNFLE patients is specific for this disorder and does not constitute a common pattern to various forms of epilepsy. The investigators will also search for a possible involvement of the nAChRs in other forms of epilepsy.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Epilepsy

    7. Study Design

    Primary Purpose
    Basic Science
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Non-Randomized
    Enrollment
    48 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Control group
    Arm Type
    Active Comparator
    Arm Title
    Non lesional diurnal partial epilepsy
    Arm Type
    Experimental
    Arm Title
    Idiopathic generalized epilepsy
    Arm Type
    Experimental
    Arm Title
    Nocturnal frontal lobe epilepsy
    Arm Type
    Experimental
    Arm Title
    Epileptic patients with Vagus Nerve Stimulation (VNS)
    Arm Type
    Experimental
    Intervention Type
    Radiation
    Intervention Name(s)
    MRI of the brain
    Intervention Description
    to eliminate a structural intra-cerebral lesion
    Intervention Type
    Radiation
    Intervention Name(s)
    PET scan [18F]F-A-85380
    Intervention Description
    exam performed after iv injection of 200 MBq [18F]F-A-85380
    Intervention Type
    Radiation
    Intervention Name(s)
    PET scan [18F]FDG
    Intervention Description
    exam performed after iv injection of 200 MBq [18F]FDG
    Primary Outcome Measure Information:
    Title
    Comparison of the cerebral distribution of the neuronal nicotinic acetylcholine receptors (nAChR) in the 5 groups of individuals by means of voxelwise and regional 18F-FA binding potential measurements
    Description
    Parametric 18F-FA and 18F-FDG binding potential measurements will be compared between the different groups of patients with epilepsy and the control group in order to find specific changes in the cerebral distribution of the nicotinic receptors in the different types of epilepsy, by using a voxel-wise (SPM) and a volume of interest (VOI) analysis.
    Time Frame
    1 month

    10. Eligibility

    Sex
    Male
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    60 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: males 18-60 years old non-smokers Exclusion Criteria: smoking during the past twelve months contraindications to MRI brain lesions on MRI (including hippocampal atrophy) neurological disorder (other than epilepsy) or psychiatric disorder neoplasia or coronary disease blood test showing : creatinine clearance < 50 ml/min, or platelet < 100 G/l, or leucocytes < 3.8 G/l, or ALT or AST > 2 x upper standard, or gamma-GT > 3 x upper standard, or albumin < 35 g/l or > 48 g/l . patients only : nuclear imaging during the past twelve months healthy volunteers only : ionising radiation exam during the past five years

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    16815873
    Citation
    Picard F, Bruel D, Servent D, Saba W, Fruchart-Gaillard C, Schollhorn-Peyronneau MA, Roumenov D, Brodtkorb E, Zuberi S, Gambardella A, Steinborn B, Hufnagel A, Valette H, Bottlaender M. Alteration of the in vivo nicotinic receptor density in ADNFLE patients: a PET study. Brain. 2006 Aug;129(Pt 8):2047-60. doi: 10.1093/brain/awl156. Epub 2006 Jun 30.
    Results Reference
    background

    Learn more about this trial

    PET Study of the Nicotinic System in Epilepsy

    We'll reach out to this number within 24 hrs